Relugolix
Indication
Treating hormone-sensitive prostate cancer (NICE TA995)
NICE TA995 - Relugolix for treating hormone-sensitive prostate cancer
Amber level 0
Brand:
Nice TA:
995
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Immune system and Malignant Disease
Background
1.1 Relugolix is recommended, within its marketing authorisation, as an option for treating prostate cancer in adults:
- with advanced hormone-sensitive prostate cancer
- alongside radiotherapy for high-risk localised or locally advanced hormone-sensitive prostate cancer
- as neoadjuvant treatment before radiotherapy for high-risk localised or locally advanced hormone-sensitive prostate cancer.
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist
Supporting documents: